Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Transplantation Proceedings

• Publication date

  1995-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 7533360
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SERUM LIPID ABNORMALITIES IN PEDIATRIC LIVER TRANSPLANT PATIENTS1

  1992cited by this paper
• Prevalence of dyslipidemia in liver transplant recipients.

  1992cited by this paper
• Distribution of FK 506 in plasma lipoproteins in transplant patients.

  1991cited by this paper
• Hyperlipidemia and obesity after orthotopic liver transplantation.

  1991cited by this paper
• Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.

  1990cited by this paper
• Effects of cyclosporine therapy on plasma lipoprotein levels.

  1989cited by this paper
• Effectiveness of orthotopic liver transplantation on the restoration of cholesterol metabolism in patients with end-stage liver disease.

  1987cited by this paper
• Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression.

  1987cited by this paper
• Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

  1986cited by this paper
• Cyclosporine improves psoriasis in a double-blind study.

  1986cited by this paper
• The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients.

  1985cited by this paper
• Hyperlipidemia after renal transplantation: natural history and pathophysiology.

  1979cited by this paper

• Immunosuppression Drugs Exhibit Differential Effects on Endothelial Cell Function

  2025cites this paper
• Immunosuppression Drugs Exhibit Differential Effects on Endothelial Cell Function

  2024cites this paper
• Cardiovascular effects of immunosuppression agents

  2022cites this paper
• Clinical trials for renal allograft tolerance induction through combined hematopoietic stem cell transplantation: A narrative review

  2022cites this paper
• Importance of Hematopoietic Mixed Chimerism for Induction of Renal Allograft Tolerance in Nonhuman Primates

  2019cites this paper
• Chimerism‐based tolerance in organ transplantation: preclinical and clinical studies

  2017cites this paper
• Clinical Transplantation Tolerance

  2014cites this paper
• Tolerance induction: hematopoietic chimerism

  2013cites this paper
• Predicting acute cellular rejection after liver transplantation: form liver function test to immune monitoring

  2013cites this paper
• Risk Factors for and Management of Post-Transplantation Cardiovascular Disease

  2012cites this paper
• Liver Transplantation: Prevention and Treatment of Rejection

  2010cites this paper
• Posttransplant metabolic syndrome: An epidemic waiting to happen

  2009cites this paper
• Prevalence and Possible Causes of Dyslipidemia after Pediatric Solid Organ Transplantation

  2008cites this paper
• Nuclear factor of activated T cell (NFAT) transcription proteins regulate genes involved in adipocyte metabolism and lipolysis.

  2007cites this paper
• Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors

  2007cites this paper
• Nutrition for the liver transplant patient

  2006cites this paper
• Tacrolimus as Intervention in the Treatment of Hyperlipidemia after Liver Transplant

  2006cites this paper
• Late Complications of Liver Transplantation and Recurrence of Disease

  2005cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation

  2004cites this paper
• Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long‐term, stable liver transplant recipients

  2004cites this paper
• Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients

  2004cites this paper
• Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin.

  2004cites this paper
• Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression.

  2002cites this paper
• Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin.

  2002cites this paper
• Calcineurin Mediates the Calcium-dependent Inhibition of Adipocyte Differentiation in 3T3-L1 Cells*

  2002cites this paper
• Lipoprotein-apolipoprotein changes in renal transplant recipients

  2002cites this paper
• Cardiovascular Toxicities of Immunosuppressive Agents

  2002cites this paper
• Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: A prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus

  2002cites this paper
• Influence of tacrolimus and prednisone on serum lipids after liver transplantation.

  2001cites this paper
• Calcineurin Inhibitors and Post-Transplant Hyperlipidaemias

  2001cites this paper
• Cardiovascular and metabolic complications after liver transplantation: Neoral- versus tacrolimus-based immunosuppression.

  2001cites this paper
• Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial.

  2001cites this paper
• Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation?

  2001cites this paper
• Nutrition in hepatic failure and liver transplantation

  2001cites this paper
• Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight

  2001cites this paper
• Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin.

  2001cites this paper
• Weight gain and cardiovascular risk after organ transplantation.

  2001cites this paper
• Long‐term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity

  2001cites this paper
• Impact and management of hyperlipidemia posttransplantation.

  2000cites this paper
• Long-term medical complications in patients surviving > or = 5 years after liver transplant.

  2000cites this paper
• [Effect of immunosuppressants on lipids].

  2000cites this paper
• Chronic Rejection of the Liver

  2000cites this paper
• Modern immunosuppression.

  2000cites this paper
• Chronic rejection of the liver: the role of immunosuppression.

  2000cites this paper
• Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

  2000cites this paper
• What Have We Learned About Primary Liver Transplantation Under Tacrolimus Immunosuppression?

  1999cites this paper
• Follow-up of the adult patient after transplantation.

  1999cites this paper
• [Hyperlipidemia in liver transplanted patients].

  1999cites this paper
• Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy.

  1999cites this paper
• What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

  1999cites this paper
• Lipid abnormalities in stable liver transplant recipients – effects of cyclosporin, tacrolimus, and steroids

  1998cites this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

  1998cites this paper
• Lipoprotein abnormalities in long‐term stable liver and renal transplanted patients. A comparative study

  1998cites this paper
• Drugs causing dyslipoproteinemia.

  1998cites this paper
• The evolution and future of immunosuppression in renal transplantation.

  1997cites this paper
• New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation

  1997cites this paper
• Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.

  1997cites this paper
• Diet therapy for organ transplantation. A problem-based approach.

  1997cites this paper
• Are me-too drugs justified?

  1997cites this paper
• Liver transplantation: current status and unresolved controversies.

  1997cites this paper
• Cardiovascular risk factors in long‐term followup after orthotopic liver transplantation

  1997cites this paper
• Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation

  1997cites this paper
• Hyperlipidemia in liver transplant recipients: prevalence and risk factors.

  1997cites this paper
• Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation.

  1997cites this paper
• Cardiovascular complications following renal transplantation

  1997cites this paper
• Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.

  1997cites this paper
• Cyclosporine and tacrolimus: the mainstay of immunosuppressive therapy for solid organ transplantation.

  1997cites this paper
• DIET THERAPY FOR ORGAN TRANSPLANTATION

  1997cites this paper
• Pathophysiology and treatment of lipid perturbation after cardiac transplantation.

  1997cites this paper
• Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation.

  1996cites this paper
• Section Review; Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Recent developments with immunosuppressant macrolides: Tacrolimus and sirolimus

  1996cites this paper
• Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy.

  1996cites this paper
• Cyclosporin and Tacrolimus in Clinical Transplantation

  1996cites this paper